PROTHENA CORPORATION PUBLIC LIMITED COMPANY Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs
PROTHENA CORPORATION PUBLIC LIMITED COMPANY (PRTA) reported Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs of $2.00 thousand for the 3-month period ending 2023-06-30, per its 10-Q filed 2024-11-12.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts · last filed 2024-11-12
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2023-06-30 was $2.00K.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2021-06-30 was $5.00K.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY adjustments to additional paid in capital, stock issued, issuance costs for fiscal 2017 was $4.90M, a 42.35% decline from fiscal 2016.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY adjustments to additional paid in capital, stock issued, issuance costs for fiscal 2016 was $8.50M, a 4.49% decline from fiscal 2015.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY adjustments to additional paid in capital, stock issued, issuance costs for fiscal 2015 was $8.90M, a 61.82% increase from fiscal 2014.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY adjustments to additional paid in capital, stock issued, issuance costs for fiscal 2014 was $5.50M, a 25.68% decline from fiscal 2013.
| Period end | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 3 month | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 12 month |
|---|---|---|
| 2023-06-30 | $2.00K 10-Q · filed 2024-11-12 | |
| 2021-06-30 | $5.00K 10-Q · filed 2022-11-03 | |
| 2017-12-31 | $4.90M 10-K · filed 2020-03-03 | |
| 2016-12-31 | $8.50M 10-K · filed 2019-03-15 | |
| 2015-12-31 | $8.90M 10-K · filed 2018-02-26 | |
| 2014-12-31 | $5.50M 10-K · filed 2017-02-27 | |
| 2013-12-31 | $7.40M 10-K · filed 2016-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |